Results 111 to 120 of about 895 (134)
Some of the next articles are maybe not open access.
Ziv-aflibercept is effective in platinum-resistant SCLC
Nature Reviews Clinical Oncology, 2014exaly +2 more sources
Ziv-aflibercept: binding to more than VEGF-A—does more matter?
Nature Reviews Clinical Oncology, 2012The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer.
Herbert Hurwitz +2 more
exaly +3 more sources
Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy
British Journal of Ophthalmology, 2018AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour +4 more
openaire +2 more sources
Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes
Ophthalmic Surgery, Lasers and Imaging Retina, 2018BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME).
Gabriel Costa, de Andrade +5 more
openaire +2 more sources
Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema
Ophthalmic Surgery, Lasers and Imaging Retina, 2017BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking ...
Mohammed, Ashraf +2 more
openaire +2 more sources
Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer
American Journal of Health-System Pharmacy, 2013Abstract Purpose The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of ziv-aflibercept in combination therapy for metastatic colorectal cancer (mCRC) are reviewed. Summary Ziv-aflibercept (Zaltrap ...
Clement, Chung, Nisha, Pherwani
openaire +2 more sources
INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina, 2019Purpose: To evaluate the 52-week safety and efficacy of intravitreal ziv-aflibercept in patients with neovascular age-related macular degeneration. Methods: All patients received three monthly intravitreal injections of 0.05 mL of ziv-aflibercept (1.25 mg) followed by a pro re nata ...
João R, de Oliveira Dias +9 more
openaire +2 more sources
Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept
Cornea, 2017Purpose: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia.
openaire +2 more sources